Prior to this study, kisspeptin had been administered using the intravenous and subcutaneous routes to over 1000 healthy men and women, as well as patients with reproductive and psychosexual disorders, without any observed adverse effects71 and therefore no safety concerns were anticipated with intranasal kisspeptin administration. This evidence concerns the gene KISS1 and psychosexual disorder.